Who We Work With
UK biotech teams running Phase I-III trials who want senior attention, transparent pricing, and a real partnership - not a hand-off to junior layers, and no redundant oversight.
Ideal clients
Series A-C companies running their first or early clinical programmes. You need experienced delivery partners, not training wheels.
Small teams with big pipelines. You don't need FTEs - you need embedded expertise that flexes with your programme demands.
University-backed ventures transitioning from preclinical to clinical. You need the full clinical infrastructure built around your science.
The DEOX difference
Not every sponsor needs a Big CRO. Not every sponsor should settle for one either.
| Big CRO | Boutique CRO | DEOX | |
|---|---|---|---|
| Senior attention | Sales team hands off to junior PMs | Senior at pitch, fading after sign | Embedded from Day 1 to closeout |
| Pricing | Opaque, margin-padded | Project-based, change-order heavy | Transparent, programme-aligned |
| AI integration | Legacy systems, slow adoption | Minimal or none | Purpose-built, BAA-covered, human sign-off |
| Delivery layers | 6+ layers between sponsor and data | 3-4 layers, variable oversight | 2 layers. Direct, accountable, senior. |
| Flexibility | Rigid scope, slow amendments | Moderate | Adaptive, sponsor-aligned |
| QMS | Standardised, bureaucratic | Variable quality | AI-assisted, inspection-ready QMS |
Honest fit
If you need 200+ sites across 15 countries, a Big CRO's global infrastructure is genuinely the better tool. We'll tell you that upfront.
We're built for pharmaceutical and biotech clinical trials. Device and diagnostics regulatory pathways are a different specialism.
If you want to sign a contract and check in at database lock, we're not your partner. We work with sponsors who want to be involved.
Let's have a 20-minute conversation. We'll tell you honestly whether DEOX is the right partner for your programme.
Start a conversation →